serine palmitoyltransferase long chain base subunit 1 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored SPTLC1P2 profile across patient tissues and cancer cell-line models. SPTLC1P2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SPTLC1P2 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, SPTLC1P2 RNA expression shows 4,284 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight KICH, COAD, and OV as cancer lineages where SPTLC1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTLC1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTLC1P2 survival associations across molecular data types. SPTLC1P2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTLC1P2 RNA expression–survival associations across cancer types. High SPTLC1P2 expression shows unfavorable associations in KICH, UCS, PAAD, BRCA, STAD and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SPTLC1P2 RNA expression.
This table summarizes SPTLC1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPTLC1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTLC1P2 shows lower tumor expression in ESCA and LUAD and higher tumor expression in COAD, STAD and LIHC. The COAD box plot shows higher SPTLC1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.270, t-test p = .039).
This table shows molecular features associated with SPTLC1P2 in patient tissues and cancer cell lines. In patient samples, SPTLC1P2 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
